Multistage vector delivery of sulindac and silymarin for prevention of colon cancer

Maria Principia Scavo, Emanuela Gentile, Joy Wolfram, Jianhua Gu, Michele Barone, Michael Evangelopoulos, Jonathan O. Martinez, Xuewu Liu, Christian Celia, Ennio Tasciotti, Eduardo Vilar, Haifa Shen

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Familial adenomatous polyposis (FAP) is an inherited condition secondary to germline mutations in the APC gene, thus resulting in the formation of hundreds of colonic adenomas that eventually progress into colon cancer. Surgical removal of the colon remains the only treatment option to avoid malignancy, as long-term exposure to chemopreventive agents such as sulindac (a non-steroidal anti-inflammatory drug) and silymarin (phytoestrogen) is not feasible. Here, we have developed a multistage silicon-based drug delivery platform for sulindac and silymarin that preferentially interacts with colon cancer cells as opposed to normal intestinal mucosa. Preferential binding and internalization of these drugs into colon cancer cells was obtained using a targeting strategy against the protein meprin A, which we demonstrate is overexpressed in human colon cancer cells and in the small intestine of ApcMin/+ mice. We propose that this delivery system could potentially be used to reduce drug-induced side effects in FAP patients, thus enabling long-term prevention of adenoma formation.

Original languageEnglish (US)
Pages (from-to)694-703
Number of pages10
JournalColloids and Surfaces B: Biointerfaces
Volume136
DOIs
StatePublished - Dec 1 2015
Externally publishedYes

Fingerprint

Sulindac
Silymarin
Colonic Neoplasms
delivery
drugs
cancer
Cells
meprin A
Adenomatous Polyposis Coli
Pharmaceutical Preparations
Adenoma
Phytoestrogens
Silicon
APC Genes
Drug delivery
intestines
Germ-Line Mutation
Anti-Inflammatory Agents
Intestinal Mucosa
mutations

Keywords

  • Colon cancer
  • Drug delivery
  • FAP
  • Multistage vector
  • Silymarin
  • Sulindac

ASJC Scopus subject areas

  • Biotechnology
  • Surfaces and Interfaces
  • Physical and Theoretical Chemistry
  • Colloid and Surface Chemistry

Cite this

Multistage vector delivery of sulindac and silymarin for prevention of colon cancer. / Scavo, Maria Principia; Gentile, Emanuela; Wolfram, Joy; Gu, Jianhua; Barone, Michele; Evangelopoulos, Michael; Martinez, Jonathan O.; Liu, Xuewu; Celia, Christian; Tasciotti, Ennio; Vilar, Eduardo; Shen, Haifa.

In: Colloids and Surfaces B: Biointerfaces, Vol. 136, 01.12.2015, p. 694-703.

Research output: Contribution to journalArticle

Scavo, MP, Gentile, E, Wolfram, J, Gu, J, Barone, M, Evangelopoulos, M, Martinez, JO, Liu, X, Celia, C, Tasciotti, E, Vilar, E & Shen, H 2015, 'Multistage vector delivery of sulindac and silymarin for prevention of colon cancer', Colloids and Surfaces B: Biointerfaces, vol. 136, pp. 694-703. https://doi.org/10.1016/j.colsurfb.2015.10.005
Scavo, Maria Principia ; Gentile, Emanuela ; Wolfram, Joy ; Gu, Jianhua ; Barone, Michele ; Evangelopoulos, Michael ; Martinez, Jonathan O. ; Liu, Xuewu ; Celia, Christian ; Tasciotti, Ennio ; Vilar, Eduardo ; Shen, Haifa. / Multistage vector delivery of sulindac and silymarin for prevention of colon cancer. In: Colloids and Surfaces B: Biointerfaces. 2015 ; Vol. 136. pp. 694-703.
@article{9bce9d1bbda24fd59c433cd29bcceef4,
title = "Multistage vector delivery of sulindac and silymarin for prevention of colon cancer",
abstract = "Familial adenomatous polyposis (FAP) is an inherited condition secondary to germline mutations in the APC gene, thus resulting in the formation of hundreds of colonic adenomas that eventually progress into colon cancer. Surgical removal of the colon remains the only treatment option to avoid malignancy, as long-term exposure to chemopreventive agents such as sulindac (a non-steroidal anti-inflammatory drug) and silymarin (phytoestrogen) is not feasible. Here, we have developed a multistage silicon-based drug delivery platform for sulindac and silymarin that preferentially interacts with colon cancer cells as opposed to normal intestinal mucosa. Preferential binding and internalization of these drugs into colon cancer cells was obtained using a targeting strategy against the protein meprin A, which we demonstrate is overexpressed in human colon cancer cells and in the small intestine of ApcMin/+ mice. We propose that this delivery system could potentially be used to reduce drug-induced side effects in FAP patients, thus enabling long-term prevention of adenoma formation.",
keywords = "Colon cancer, Drug delivery, FAP, Multistage vector, Silymarin, Sulindac",
author = "Scavo, {Maria Principia} and Emanuela Gentile and Joy Wolfram and Jianhua Gu and Michele Barone and Michael Evangelopoulos and Martinez, {Jonathan O.} and Xuewu Liu and Christian Celia and Ennio Tasciotti and Eduardo Vilar and Haifa Shen",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.colsurfb.2015.10.005",
language = "English (US)",
volume = "136",
pages = "694--703",
journal = "Colloids and Surfaces B: Biointerfaces",
issn = "0927-7765",
publisher = "Elsevier",

}

TY - JOUR

T1 - Multistage vector delivery of sulindac and silymarin for prevention of colon cancer

AU - Scavo, Maria Principia

AU - Gentile, Emanuela

AU - Wolfram, Joy

AU - Gu, Jianhua

AU - Barone, Michele

AU - Evangelopoulos, Michael

AU - Martinez, Jonathan O.

AU - Liu, Xuewu

AU - Celia, Christian

AU - Tasciotti, Ennio

AU - Vilar, Eduardo

AU - Shen, Haifa

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Familial adenomatous polyposis (FAP) is an inherited condition secondary to germline mutations in the APC gene, thus resulting in the formation of hundreds of colonic adenomas that eventually progress into colon cancer. Surgical removal of the colon remains the only treatment option to avoid malignancy, as long-term exposure to chemopreventive agents such as sulindac (a non-steroidal anti-inflammatory drug) and silymarin (phytoestrogen) is not feasible. Here, we have developed a multistage silicon-based drug delivery platform for sulindac and silymarin that preferentially interacts with colon cancer cells as opposed to normal intestinal mucosa. Preferential binding and internalization of these drugs into colon cancer cells was obtained using a targeting strategy against the protein meprin A, which we demonstrate is overexpressed in human colon cancer cells and in the small intestine of ApcMin/+ mice. We propose that this delivery system could potentially be used to reduce drug-induced side effects in FAP patients, thus enabling long-term prevention of adenoma formation.

AB - Familial adenomatous polyposis (FAP) is an inherited condition secondary to germline mutations in the APC gene, thus resulting in the formation of hundreds of colonic adenomas that eventually progress into colon cancer. Surgical removal of the colon remains the only treatment option to avoid malignancy, as long-term exposure to chemopreventive agents such as sulindac (a non-steroidal anti-inflammatory drug) and silymarin (phytoestrogen) is not feasible. Here, we have developed a multistage silicon-based drug delivery platform for sulindac and silymarin that preferentially interacts with colon cancer cells as opposed to normal intestinal mucosa. Preferential binding and internalization of these drugs into colon cancer cells was obtained using a targeting strategy against the protein meprin A, which we demonstrate is overexpressed in human colon cancer cells and in the small intestine of ApcMin/+ mice. We propose that this delivery system could potentially be used to reduce drug-induced side effects in FAP patients, thus enabling long-term prevention of adenoma formation.

KW - Colon cancer

KW - Drug delivery

KW - FAP

KW - Multistage vector

KW - Silymarin

KW - Sulindac

UR - http://www.scopus.com/inward/record.url?scp=84945130583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945130583&partnerID=8YFLogxK

U2 - 10.1016/j.colsurfb.2015.10.005

DO - 10.1016/j.colsurfb.2015.10.005

M3 - Article

VL - 136

SP - 694

EP - 703

JO - Colloids and Surfaces B: Biointerfaces

JF - Colloids and Surfaces B: Biointerfaces

SN - 0927-7765

ER -